According to the agency, the same risk-benefit analysis does not hold true for restless-leg syndrome.

FORBES: FDA Concerns Shake XenoPort, DepoMed

Whistle-blowers undoubtedly face significant risk and must do cost-benefit analysis to decide whether to come forward.

FORBES: Put Your Money Where Your Mouth Is